HFS
SUPN icon

Hantz Financial Services’s Supernus Pharmaceuticals SUPN Stock Holding History

Hantz Financial Services’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$60K Buy
1,288
+162
+14% +$7.78K ﹤0.01% 1598
2026
Q1 		$58K Buy
1,126
+43
+4% +$2.19K ﹤0.01% 1500
2025
Q4 		$54K Buy
1,083
+458
+73% +$22.3K ﹤0.01% 1407
2025
Q3 		$30K Buy
625
+281
+82% +$11.3K ﹤0.01% 1423
2025
Q2 		$11K Buy
+344
New +$11K ﹤0.01% 1487

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Hantz Financial Services's SUPN Position: Q2 2026 in Review

Hantz Financial Services increased its Supernus Pharmaceuticals (SUPN) stake by 14% in Q2 2026, buying an estimated $7.78K and bringing the position to 1,288 shares worth $60K. The position accounts for ﹤0.01% of the portfolio, ranked #1598.

Hantz Financial Services first reported a position in SUPN in Q2 2025 and has held it in 5 quarters since. 335 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Hantz Financial Services held 1,288 shares of Supernus Pharmaceuticals worth $60K as of Q2 2026.
  • Hantz Financial Services bought 162 Supernus Pharmaceuticals shares in Q2 2026, an estimated $7.78K.
  • Supernus Pharmaceuticals made up ﹤0.01% of Hantz Financial Services's portfolio in Q2 2026, its #1598 holding.
  • Hantz Financial Services first reported a position in Supernus Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 335 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Hantz Financial Services's 13F filing for Q2 2026, filed 13 Aug 2026.